Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4538-126: Nivolumab for rhabdoid tumor
jRCT2051240150Phase 2Recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in malignant rhabdoid tumor (MRT), sponsored by Ono Pharmaceutical. Primary endpoint: Objective response rate (central review). Started Nov 2024; status: recruiting.
02
Drugs
03
Conditions
malignant rhabdoid tumor (MRT)
Beyond the preview
Go deeper on jRCT2051240150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240150.